NCT05426746View on ClinicalTrials.gov

First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

May 18, 2023

Study Completion Date

May 18, 2023

Conditions
ARDS, Human
Interventions
DRUG

ALT-100

intravenous infusion of drug substance diluted in 0.9% normal sterile saline

OTHER

Normal Saline

intravenous infusion of placebo (0.9% normal sterile saline)

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
lead

Aqualung Therapeutics Corp.

INDUSTRY

NCT05426746 - First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100 | Biotech Hunter | Biotech Hunter